Patient Blood Management in Liver Surgery

Fuat H. Saner



Department of General-, Visceral- and Transplant Surgery



Conflicts of Interest

- CSL Behring GmbH
- Werfen
- MSD
- AstraZeneca
- Gilead
- Biotest



Reason for liver resection



Department of General-, Visceral- and

Transplant Surgery

Latchana, Langenbecks Archives of Surgery , 2019, 404: 1-9



Blood loss and transfusion in hepatectomy

- Transfusion rate 25.2%-56.8%
- Reason for differences
 - Different patient population
 - Different time line
- Data base provides inside into nature of the problem



Short term outcome and higher rate of Transfusion

- Higher surgical morbidity with increased transfusion rate
 - 28.3% vs. 11.1 % (p < 0.0001)</p>
- Higher 30-day Mortality
 - 5.6% vs. 1%
- Multivariate Analysis and risk adjustment
 - RBC transfusion independet risk factor for morbidity (RR = 1.8) and 30-day Mortality (RR = 3.62)
- Immunmodulatory effects
 - Higher susceptibility to infection/Sepsis

Vamvakas, Blood Rev 2007 21 (6): 327-348 Hallet, HepatoBiliary Surg Nutr. 2018, 7 (1); 1-10

Department of General-, Visceral- and Transplant Surgery



Oncologic outcomes

Overall survival



Recurrence free survival



niversitätsklinikum Essen



Transplant Surgery

Hallet, Ann Surg Oncol, 2015, DOI10.1245/s10434-015-4477-4

Many reasons to avoid transfusion

Department of General-, Visceral- and Transplant Surgery



Patient blood management in Liver surgery



Department of General-, Visceral- and Transplant Surgery



Preop. Assessment of Bleeding Risk

- Medical coagulation history patient
- Extent and location of resection => risk of bleeding
- Resection in cirrhosis?
- Laboratory



Assessment of bleeding risk

Traditional approach

- Coagulation profile (PT; aPTT)
- Platelet count

Point of care (Viscoelastic tests)

Rotem

TEG

Department of General-, Visceral- and Transplant Surgery



Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedure. An evidence-based review

One trial and 24 oberservational studies

CONCLUSION: There is insufficient evidence to conclude that abnormal test results predict bleeding. Randomized controlled trials should be performed to provide stronger evidence for clinical decision making regarding preprocedure transfusion.



Segal, Transfusion 2005; 45: 1413-1425

Standard laboratory test (SLT) and assessment of bleeding risk

Meta-analysis: Coagulopthy: 1,5-times prolonged INR, aPTT

> Total 1123 publication scanned => 64 publication (53 studies SLT + 11 guidelines)

> > All data =>3 prospective studies with 108 Patienten, no RCT

> > > Conclusion: no sound evidence from well-designed studies that confirm the usefulness of SLTs for diagnosis or to guide treatment of coagulopathy



TEG guided coagulation management before invasive procedure



Pietri, Hepatology 2015, doi: 10.1002/hep.28148T



TEG guided coagulation management before invasive procedure

	SLT	TEG	p-value
Transfusion rate	100%	16,7%	<0.0001
FFP	53.3%	0% alone	0.0001
Platelet	33.3%	6.7%	0.009
FFP+platelet	13.3%	10%	n.s.
Post-Procedure HB	9,9 ± 1.2	10.7 ± 1.8	0.043
Postprocedure related bleeding	1 (3.3%)	0	0.313
Postprocedure INR	1.75 ± 0.41	1.9 ± 0.64	0.225
Postprocedure Platelet count	58.3 ± 31.3	55.2 ± 27.5	0.692

Pietri, Hepatology 2015, doi: 10.1002/hep.28148T



Alterations in coagulation following major liver resection



CI. Dashed lines are reference ranges. *p < 0.01 compared with baseline.



Mallett, Anaesthesia 2016, 71 657-668

Department of General-, Visceral- and Transplant Surgery



Alterations in coagulation following major lliver resection



Patients are at risk for thrombosis



Mallett, Anaesthesia 2016, 71 657-668

Department of General-, Visceral- and Transplant Surgery



Liver Failure and Risk of Thrombosis

- Registry data from Denmark 1980-2005
- N= 496 872, whereas 99 444 pulmonary embolism

Table 4. Relative risks^a (odds ratios) and 95% CIs for VTE

	All venous thro	mboembolism	Unprovoked venous thromboembolism		
Variable	Crude RR	Adjusted ^b RR	Crude RR	Adjusted ^c RR	
Liver cirrhosis	2.60 (2.34–2.88)	1.74 (1.54–1.95)	2.88 (2.52–3.29)	2.06 (1.79–2.38)	
Non-cirrhotic liver disease	2.54 (2.36–2.73)	1.87 (1.73–2.03)	2.84 (2.59–3.11)	2.10 (1.91–2.31)	
Liver cirrhosis and HCC	2.64 (2.38–2.93)	1.75 (1.56–1.97)	2.90 (2.54–3.32)	2.08 (1.81–2.40)	

HCC, hepatocellular carcinoma.

^aComputed with conditional logistic regression. ^bAdjusted for cancer, fractures, trauma, surgery, pregnancy, Charlson Index, psychiatric diseases, and obesity. ^cAdjusted for Charlson Index, psychiatric diseases, and obesity.

Søgaard, Am J Gastro 2009, 104, 96-101



Increased platelet adhesion and aggregation due increased vWF



Endothel Thrombin generation increased und Protein C serum level decreased



Gatt, Journal of Thrombosis and Hemostasis, 2010, 8: 1994-2000 Tripodi, Gastroenterology 2009: 137: 2105-2111 Department of General-, Visceral and Transplant Surgery



Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen







North Pacific Surgical Association: The INR overestimates coagulopathy in patients after major hepatectomy

Abstract

BACKGROUND: The International Normalized Ratio (INR) is commonly used to guide therapy after hepatectomy. We hypothesized that the use of thrombelastography (TEG) would demonstrate a decreased incidence of hypocoagulability in this patient population.

METHODS: Seventy-eight patients were prospectively enrolled before undergoing hepatectomy. INR, TEG, and coagulation factors were drawn before incision, postoperatively, and on postoperative days 1, 3, and 5.

RESULTS: Patients demonstrated an elevated INR at all postoperative time points. However, TEG demonstrated a decreased R value postoperatively, with subsequent normalization. Other TEG measurements were equivalent to preoperative values. All procoagulant factors save factor VIII decreased postoperatively, with a simultaneous decrease in protein C.

CONCLUSIONS: TEG demonstrated a brief hypercoagulable state after major hepatectomy, with coagulation subsequently normalizing. The INR significantly overestimates hypocoagulability after hepatectomy and these data call into question current practices using the INR to guide therapy in this patient population.

© 2014 Elsevier Inc. All rights reserved.



Liver surgery and thrombosis

N = 27 Pat. With Cholangio-cellular cancer vs. Living donor **Right hepatectomy**

	Control (n = 17)	Cholangio carcinoma (n = 27)	Unadjusted P value	Bonferroni-adjusted P value	Normal range
CT (e)	67 (58-74)	61 (52-68)	0.072	0.576	40-80
CFT (s)	106 (85-123)	56 (48-79)	0.000	0.001	50-150
v-Max (mm/s)	12 (11-15)	22 (19-28)	0.000	0.000	-
t-Max (s)	126 (99-145)	86 (76-104)	0.007	0.055	-
AUC	6412 (6049-6632)	7354 (6687-7684)	0.000	0.000	-
MCF (mm)	64 (61-66)	74 (67-77)	0.000	0.000	50-70
G (dynes/cm ²)	8759 (7713-9841)	13622 (9143-16742)	0.000	0.006	5-12×10 ⁹
ML%	10 (9-13)	4 (9-13)	0.131	1.000	<15%

Table 3 Thromboelastometry data (initiation, propagation, firmness, and lysis) of control and cholangiocarcinoma group

Data are shown as median (IQR). AUC, area under the curve; CFT, clot formation time; CT, clotting time; MCF, maximum clot firmness; ML, maximum lysis; t-Max, time to reach the maximum velocity; v-Max, maximum velocity.



- 6 Thrombotic events only in the Cancer group
 - 4 portal vein thrombosis
 - 2 deep vein thrombosis





Thrombin Level (nM)

Diagnoses and treatment guided with Visco-elastic tests



Thrombin Generation



Department of General-, Visceral and Transplant Surgery



Turn around time SLT vs. Rotem

- For better comparison both devices in Lab
- SLT: 53 min vs 23 min. POC , p< 0.001</p>
- If POC is bedside: turn around time < 10 min (A5)</p>





Intraoperative Strategies to avoid bleeding

- Pringle maneuver (portal pedicle clamping)
- $CVP \le 5 mmHg$
- Fluid restriction
- Hemostatic agents (oxidized ceullulose, fibrin, collagen)
- Antifibrinolytics



Pringle Maneuver

- First described in 1908
 - Clamping 10-20 min, with 5 min gap for reperfusion



- It was shown to be safe up to 120 min
- Concern:
 - Postop liver (ischemic hepatitis)
 - Earlier recurrence of malignant tumor (Ischemia/Reperfusion)
- Cochrane Database systematic Review
 - Well tolerated
 - Reduce blood loss
 - No Difference in term of Morbidity and Mortality



CVP and liver surgery



R M Jones et al British Journal of Surgery 1998, 85, 1058–1060



Anesthesia Care for Adult Live Donor Hepatectomy: Our Experiences With 100 Cases



Department of General-, Visceral- and

Chhibbar, Liver Transplantation, 2007, 13:537-542 Transplant Surgery



Low CVP in ESLD

- Among 500 LTX 79.6% without blood products (Transfusion 2012; 93: 1276-1281)
- Impact of Phlebotomy and phenylephrine on PVP and CVP before and after Intervention

Massicotte, Transplantation 2010; 89: 920-927

Department of General-, Visceral and Transplant Surgery



Effect on CVP

Central venous pressure

	Before phleboto (mm Hg	e my p g)	After hlebotor (mm Hg	my g) Delta 1	After phenyleph (mm H	nrine g)
	14		8	0.4	11]
	12		6	0.5	8	
	10		4	0.6	9	
	12		7	0.4	10	
	13		8	0.4	11	
	13		8	0.4	14	
	18		7	0.6	13	
	21		15	0.3	17	
	9		5	0.4	8	
	15		7	0.5	12	
Median	13		07		11	
		De	partment of G Transpl	General-, Visceral and ant Surgery	Massicone, T	ransplantation 2010; 89 Universitätsklinik

Effect on PVP

	Portal venous pressure						
Before phlebotomy (mm Hg)	r ph (After lebotom mm Hg)	y Delta 1	pher (r	After nylephrii nm Hg)	ne Delta 2	
32		19	0.4		18	0.1	
24		12	0.5		13	-0.1	
32		15	0.5		15	0	
13		7	0.5		8	-0.1	
29		19	0.3		15	0.2	
12		8	0.3		7	0.1	
9		4	0.6		5	-0.3	
14		10	0.3		10	0	
8		3	0.6		3	0	
10		4	0.6		3	0.3	
18		09		•	09		
	C	Department o Trans	f General-, Viscera splant Surgery	al and	Massico	otte, Transplantat Universi	

Median

Systematic Review on 1148 Patients- Evaluation CVP for volume replacement (total 51 studies)



AUC-ROC

Esekesen, Int. Care Med. 2016, 42: 324-332

Department of General-, Visceral and 332 Transplant Surgery



Central venous pressure and liver resection: a systematic review and meta-analysis

Abstract

Background: A liver resection under low central venous pressure (CVP) has become standard practice; however, the benefits beyond a reduction in blood loss are not well reported. Moreover, the precise method to achieve CVP reduction has not been established. A systematic review and metaanalysis of randomized controlled trials (RTCs) was performed to assess the effects of CVP on clinical outcome and to identify the optimum method of CVP reduction.

Reduction ranges from 308-406 ml blood

anaootriotio nor ourgiour motriodo or

reduction were associated with a reduced post-operative morbidity.

IT the fear off groups, reacher

Conclusion: Low CVP surgery is associated with a reduction in EBL; however, this does not translate into an improvement in post-operative morbidity. The optimum method of CVP reduction has not been identified.

Department of General-, Visceral- and Transplant Surgery



Hughes, HPB, 2015, 17, 863-871

Fluid restriction in liver surgery is benefical



transient portal hypertension

Klinik für Allgemein-, Viszeral- und Transplantationschirurgie



Use of antifibrinolytics

- Hyperfibrinolysis is shown in Trauma, liver transplantation, cardiac surgery
- In liver resection unknown
- Blind Use of antifibrinolytics was common in the frist decade 2000 to avoid blood loss



Use of antifibrinolytics in liver surgery

Author	Journal	Drug	Year	Operation	Number of patients	Transfusion requiremen t	Thromb- osis	
Porte (RCT)	Lancet	Aprotinin	2000	LT	46/43/48	Decreased 37%	no	
Wu	S	നി	iee	Var		ിപ്പ		
Mol (Syst		GUUU	ାତ୍ର		y O		ec	Ł
revie C	han	ge	of n	nan	age	eme	nt	
Kara olas	ſ		obi	lst (dat	a	d	
		,			lysis)			

Department of General-, Visceral- and Transplant Surgery



Liver resection Medical Center University Duisburg-Essen in 1/2015 - 10/2016 (≥ 2 segment resection)

ICU stay (days)	1.8 (0.9-4.1)
Ventilation time (h)	12.25 (5.3-52.58)
Hospital stay (days)	11.2 (14-136.1)
Transfusion rate	7.5% (37/493 Patients)
Transfused RBC in transfused Pat.	4 (1-5.5)
In-house mortality (%)	6.6



Policy Essen liver surgery

- Low transfusion trigger (7 g/dl and sometimes less)
- Coagulation management => VET-guided coagulation concentrate replacement, no FFP
- Fluid restriction
- CVP appreciates not so much attention (Surgeons quit to ask CVP numbers)



Case report-60 ys. Old patient

- 60 ys old male patient
- Klatskin tumor type Bismuth IIIa
- IDDM
- Smoker
- Operation:
- Extended right hepatectomy (right hepatectomy + Seg IV)
- Resection bile duct and Hepatico-Jejunostomy
- Infiltration of Portal vein => PV resection and reconstruction
- Duration: 5 hours, 5000 ml Cristalloids, 1000 ml Colloids, 2 RBC





ICU admission and the first 24 h

Liver	bilirubin: 5.2 mg/dl= 88.9 μmol/L (12 h after ICU admission)
Kidney	10ml/h (< 0.5 ml/kg/h) within first 24 h
Hemodynamic	Norepinephrine 1.2 µg/kg/min
Ventilation	BIPAP, P _{insp} = 25 mbar, PEEP = 10 mbar, FiO ₂ = 60% Horovitz-Index: 175 mmHg



ICU Course-lab course PT and bilirubin



Grade C postop Liver Failure



Can we forecast bleeding?

- ROTEM/TEG assessment results in a higher transfusion threshold
- Primarly clinical use VET for intra-/postop to guide coagulation management
- Question: what are the lower limits of TEG/ROTEM preprocedural?
- No studies about predicting bleeding for invasive procedure



What brings us the future?

Time to change the classical vision of coagulation in liver disease: from the balance dysequilibrium to the systems biological network modelling



"A new scientific truth does not prevail in such a way that its opponents are convinced and taught to be learned, but rather by the fact that their opponents are gradually becoming extinct and that the adolescent generation is acquainted with the truth in advance."



Max Planck, 1858-1947

In 1919 he was awarded the Nobel Prize for Physics of the Year 1918 for the discovery of Planck's quantum of action

> Department of General-, Visceral- and Transplant Surgery



Oncologic outcomes

- Several reasons for inferior outcome after liver resection
 - Suboptimal resection
 - Postop complictaion
 - Transfusion with possible immunmodulatory and inflammatory effect
 - Retrospective study with 5 yr follow-up

